Among the recurrent lesions in pediatric patients, fusions involving lysine methyltransferase 2A (KMT2A, MLL) are considered hallmarks of aggressive AML, particularly in infants and early childhood. The gene discussed is KMT2A; the disease is acute myeloid leukemia.